Published in AIDS Res Hum Retroviruses on August 03, 2012
An action agenda for HIV and sex workers. Lancet (2014) 1.06
Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago. PLoS One (2014) 0.81
Immunology in Africa. Trop Med Int Health (2015) 0.80
The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'. Trop Med Int Health (2014) 0.79
Analysis of the history and spread of HIV-1 in Uganda using phylodynamics. J Gen Virol (2015) 0.78
Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. PLoS One (2017) 0.75
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med (2015) 2.28
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89
HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Infect (2011) 1.75
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol (2008) 1.71
HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS (2004) 1.63
HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses (2011) 1.63
High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis (2012) 1.62
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Host-pathogen interaction in invasive Salmonellosis. PLoS Pathog (2012) 1.57
HIV incidence and recent injections among adults in rural southwestern Uganda. AIDS (2007) 1.48
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS (2011) 1.44
Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health (2008) 1.44
HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda. AIDS (2007) 1.41
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
Effect of pregnancy on HIV disease progression and survival among women in rural Uganda. Trop Med Int Health (2007) 1.35
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS (2010) 1.29
High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc (2013) 1.28
Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses (2012) 1.23
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Access to, and uptake of, antiretroviral therapy in a developing country with high HIV prevalence: a population-based cohort study in rural Uganda, 2004-2008. Trop Med Int Health (2012) 1.16
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15
The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999-2009. Trop Med Int Health (2012) 1.15
Breast abscess caused by Propionibacterium avidum following breast reduction surgery: case report and review of the literature. J Infect (2005) 1.13
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest (2014) 1.12
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis (2013) 1.12
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Antiretroviral therapy and sexual behavior in Uganda: a cohort study. AIDS (2011) 1.06
First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ (2002) 1.06
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses (2010) 1.04
Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. J Gen Virol (2013) 1.02
Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS (2002) 1.01
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr (2010) 1.01
Using verbal autopsy to assess the prevalence of HIV infection among deaths in the ART period in rural Uganda: a prospective cohort study, 2006-2008. Popul Health Metr (2011) 1.00
Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine (2013) 0.99
Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Hum Retroviruses (2007) 0.98
The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res Hum Retroviruses (2004) 0.98
Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans. PLoS One (2009) 0.97
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob Agents Chemother (2011) 0.96
HIV-1 subtype dynamics over 10 years in a rural Ugandan cohort. Int J STD AIDS (2004) 0.95
Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Rev (2015) 0.94
HIV vaccines: current status worldwide and in Africa. AIDS (2010) 0.94
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther (2012) 0.94
Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology (2011) 0.93
Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population. Immunogenetics (2013) 0.93
EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health (2013) 0.93
Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria. AIDS Res Hum Retroviruses (2013) 0.91
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans. AIDS Res Hum Retroviruses (2004) 0.90
Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis (2004) 0.90
Human immunodeficiency virus type 1 Western blot: revised diagnostic criteria with fewer indeterminate results for epidemiological studies in Africa. Int J Epidemiol (2002) 0.88
An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries. AIDS (2010) 0.88
Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda. AIDS Res Hum Retroviruses (2006) 0.88
Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. J Leukoc Biol (2005) 0.87
Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine (2004) 0.87
Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J Virol (2013) 0.87
The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda. J Acquir Immune Defic Syndr (2012) 0.86
Estimating incidence of HIV infection in Uganda. JAMA (2009) 0.85
Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine (2007) 0.85
Support for the RV144 HIV vaccine trial. Science (2004) 0.85
HIV-1 subtype distribution trends and evidence of transmission clusters among incident cases in a rural clinical cohort in southwest Uganda, 2004-2010. AIDS Res Hum Retroviruses (2012) 0.84
A polymorphism that reduces RANTES expression is associated with protection from death in HIV-seropositive Ugandans with advanced disease. J Infect Dis (2006) 0.84
HIV type 1-specific inter- and intrasubtype cellular immune responses in HIV type 1-infected Ugandans. AIDS Res Hum Retroviruses (2004) 0.84
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health (2015) 0.83
Deciphering the complex distribution of human immunodeficiency virus type 1 subtypes among different cohorts in Northern Tanzania. PLoS One (2013) 0.81
Effect of HIV-1 subtypes on disease progression in rural Uganda: a prospective clinical cohort study. PLoS One (2013) 0.81
Transmitted antiretroviral drug resistance among drug-naive female sex workers with recent infection in Kampala, Uganda. Clin Infect Dis (2012) 0.81
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother (2013) 0.81
Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study. PLoS One (2012) 0.80
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. Retrovirology (2011) 0.80